Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS-8873
- Development stage
- Discontinued
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GS-8873 is a preclinical, orally bioavailable small-molecule hepatitis B virus (HBV) surface antigen (HBsAg) suppressor developed by Gilead Sciences for the treatment of chronic hepatitis B. It is a dihydropyridophthalazinone (DPP) compound that acts as an inhibitor of the human poly(A) polymerases PAPD5 and PAPD7 (PAPD5/7). By inhibiting PAPD5/7, GS-8873 destabilizes and promotes the degradation of HBV RNA transcripts, leading to potent suppression of HBsAg production with an EC50 of approximately 4 nM. Although nominated as a development candidate with projected once-daily dosing at a human dose under 5 mg, its development was halted during preclinical safety assessments after 13-week toxicity studies in rats and cynomolgus monkeys revealed a liability for neurotoxicity, specifically peripheral neuropathy and neuroelectrophysiology deficits.
- Other names
- HBV-IN-19HBV-IN19HBV-IN 19
02
Targets
TENT4A (Terminal nucleotidyltransferase 4A)TENT4B
Beyond the preview
Go deeper on GS-8873.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS-8873.